Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased towa...

Descripción completa

Detalles Bibliográficos
Autores: Shi, L, Westwood, S, Baird, AL, Winchester, L, Dobricic, V, Kilpert, F, Hong, SJ, Franke, A, Hye, A, Ashton, NJ, Morgan, AR, Bos, I, Vos, SJB, Buckley, NJ, ten Kate, M, Scheltens, P, Vandenberghe, R, Gabel, S, Meersmans, K, Engelborghs, S, De Roeck, EE, Sleegers, K, Frisoni, GB, Blin, O, Richardson, JC, Bordet, R, Molinuevo, JL, Rami, L, Wallin, A, Kettunen, P, Tsolaki, M, Verhey, F, Lleo, A, Alcolea, D, Popp, J, Peyratout, G, Martinez-Lage, P, Tainta, M, Johannsen, P, Teunissen, CE, Freund-Levi, Y, Frolich, L, Legido-Quigley, C, Barkhof, F, Blennow, K, Zetterberg, H, Baker, S, Morgan, BP, Streffer, J, Visser, PJ, Bertram, L, Lovestone, S, Nevado-Holgado, AJ
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p2359
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2359
Access Level:acceso abierto
Palabra clave:Amyloid beta
SOMAscan assay
Plasma proteomics
Replication
Causal relationship
Tau
Descripción
Sumario:Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) e4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition. (C) 2019 The Authors. Published by Elsevier Inc.

Similares en LA Referencia